

**APCCC Detailed Programme 2019
(subject to minor changes), speakers to be confirmed**

Areas of controversy

1. Locally advanced prostate cancer
2. Biochemical recurrence of prostate cancer after local therapy
3. Management of primary tumour in the metastatic situation
4. Newly diagnosed metastatic prostate cancer, including oligometastatic prostate cancer
5. Management of nmCRPC
6. Management of mCRPC
7. Bone and bone metastases
8. Molecular characterization: Tissue and blood
9. Heterogeneity of men with prostate cancer (ethnicity, elderly)
10. Side effects of hormonal treatments and their management

Thursday 29th August 2019

Time	Session	
09:00 – 09:15	Welcome Address Silke Gillesen and Aurelius Omlin on behalf of APCCC	
9:15 - 10:45	Molecular biomarkers and novel imaging in APC	Chairs: Bristow, Padhani, Gleave
	State of the art on molecular characterization in APC - Non-metastatic prostate cancer - Metastatic castration-naïve - Metastatic CRPC	Pritchard
	Clinical utility of molecular markers	De Bono
	Which men need genetic counselling and/or testing?	Eeles
Discussion		
	Advantages and pitfalls of PSMA PET/CT in APC imaging • Advantages • Pitfalls	Fanti Davis
Discussion (10min)		
10:45 – 11:15 COFFEE BREAK		
11:15 – 12:45	Node-positive prostate cancer (N1 but M0)	Chairs: Feng, Briganti, Higano
	Session 2	
	How to treat men with newly diagnosed cN1 cM0 a) based on classical imaging b) based on novel (next-generation) imaging	
	• Surgery options	Murphy
	• Radiation therapy options	Roach
	• Systemic therapy options	James
	Synthesis – How best to treat cN1 prostate cancer	Fizazi
Discussion		
	How to treat men with pathological node positive (pN1, cM0) prostate cancer?	Bossi

Discussion		
12:45 – 13:45 LUNCH		
13:45 – 15:15 Session 3	PSA recurrence after radical local therapy and oligometastatic prostate cancer	Chairs: Khauli, Sternberg, Zapatero
Management of men with PSA recurrence after radical local radiation therapy		Feng
Management of men with PSA recurrence or persistence after prostatectomy		Evans
Discussion		
Oligometastatic prostate cancer – Definitions and concepts		Reiter
De novo (newly diagnosed) oligometastatic prostate cancer		Morris
Oligorecurrent prostate cancer after local therapy		Ost
Please cover: Which patients should receive local, systemic, and/or metastasis-directed therapy?		
Oligometastatic and oligoprogressive CRPC		Small
Please cover: Progression after treatment for nmCRPC, progression on ADT + AR pathway inhibitors, and patients with metastatic disease who have only a few progressing lesions (oligoprogression)		
Discussion		
15:15 – 15:45 COFFEE BREAK		
15:45 – 17:15 Session 4	Regional care (demographic and environmental factors)	Chairs: Halabi, Kanesvaran, Suzuki
Ethnicity and prognosis		Logothetis
Pharmaco-ethnicity and impact on treatment		Poon
Report and lessons learned from the consensus conference for developing countries		Maluf
Disparities in prostate cancer management in the U.S.		Morgans
The ageing population: Oncogeriatric assessment and treatment considerations		O'Sullivan
Discussion		

Friday 30th August 2019		
Extra session 08:00 – 08:30	Movember Session	
Outcomes Research – Ironman project		Kantoff
Discussion		
08:30 – 10:15 Session 5	Management of metastatic castration-sensitive/naive prostate cancer	Chairs: Attard, Mottet
Testosterone measurement – Which test and when?		Gleave
Local treatment of the primary (RT) in the metastatic situation		Bristow
Local treatment of the primary tumour (surgery) in the metastatic situation		Steuber
Discussion		
Which systemic therapy for which patient with newly diagnosed metastatic prostate cancer?		Sweeney
Addition of AR pathway inhibitors vs. docetaxel: Statisticians' perspective		Sydes
Synthesis – Optimal treatment of men with newly diagnosed prostate cancer		Clarke
Follow-up on ADT alone vs. ADT “plus”		Beer
Discussion		
10:15 – 10:45 COFFEE BREAK		
10:45 – 12:45 Session 6	Management of castration-resistant prostate cancer (CRPC)	Chairs: Murthy, Duran
Definition and overview of treatment options in nmCRPC		Scher
Debate: Treatment of nmCRPC <ul style="list-style-type: none"> • Pros • Cons 		Hussain Higano
First-line mCRPC after ADT + Docetaxel or AR pathway inhibitor		Taplin
Subgroup analysis of mCRPC clinical trials		Halabi
Discussion		
PSMA targeted therapies		Hofman
Immunotherapy		Drake
PARP inhibition		Chi
Neuroendocrine spectrum: Diagnosis and treatment		Efstathiou
Discussion		
12:45 – 13:45 LUNCH		

13:45 – 14:45 Session 7	Side effects of treatment and their management	Chairs: Bjartell, Leibowitz, Heidenreich
Management of sexuality and incontinence issues in APC		Van Oort
Management of hot flushes		Frydenberg
Management of metabolic changes		Shore
Management of fatigue, cognition/dementia		Ryan
Optimal steroid use with abiraterone		Attard
Discussion		
14:45 – 15:15 COFFEE BREAK		
15:15 – 16:45 Session 8	Bone and bone metastases	Chairs: Heinrich, Türkeri
Prevention/Treatment of osteoporosis		Saad
Debate: Antiresorptive therapy to reduce SRE risk in men with bone-metastatic CRPC		
<ul style="list-style-type: none"> • Only for very select men with CRPC and bone metastases 		Parker
<ul style="list-style-type: none"> • For the majority of men with CRPC and bone metastases 		Tombal
<ul style="list-style-type: none"> • Synthesis – Best use of antiresorptive therapy in CRPC 		Smith
Discussion		
Radium-223 and bone health agents		Sartor
The flare phenomenon in bone-metastatic APC		Padhani
Discussion		
16:45 – 17:15 COFFEE BREAK		
17:15 – 18:15 Session 9	The future of APC management	Chair: Sade, Mrabti, Soule
Wishes from a patient's perspective		Millman
In locally advanced prostate cancer		Briganti
In oligometastatic prostate cancer		Beltran
In polymetastatic prostate cancer		Oh
In imaging		Fanti
In biomarkers		Rubin
Global access to treatments		Fizazi
Discussion		

Saturday 31st of August 2019		
Time	Special Session All participants will be able to attend the panel meeting as part of the conference.	Speakers
08:30 – 10:30	Consensus Panel – Discussion and votes on consensus questions – Part 1	ALL PANEL MEMBERS Moderation: Small and Tombal
10:30 – 11:00 COFFEE BREAK		
11:00 – 13:00	Consensus Panel – Discussion and votes on consensus questions – Part 2	ALL PANEL MEMBERS Moderation: Small and Tombal
Closing Remarks: S.Gillessen and A.Omlin		